We help biopharmaceutical companies run and manage their clinical trials using our cloud B2B software.
- Proof of concept June 2017
- First Market Release of Engility® Trial Management June 2019
- First customer signed up October 2019
- PHARMASEAL wins East Midlands Medilink Start Up award Dec 2019
PHARMASEAL is a software company that is disrupting how clinical trials are managed in its mission to bring new medicines to market faster. Engility® is a new cloud B2B platform, designed for the thousands of global SME companies developing new drugs and medical devices. Typically companies use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Engility® simplifies control by providing a single management platform allowing information to be centralised and accessed from a single platform. With Engility®, companies and suppliers can collaborate, improving the productivity of the supply chain and as a result, their clinical trials. SME companies are critical in developing new medical innovations. Engility® can transform the productivity of the SME sector through the digitisation of processes. Join us in reimagining how future clinical trials are managed.
PHARMASEAL is a software B2B business selling to pharmaceutical, biotechnology, medical device and contract research organisations engaged in running clinical trials for the approval of new medicines and medical devices. The primary source of revenue is a SaaS software subscription license to use the Engility® platform. Typical contracts will be for a 3-year term license with annual payment in advance. Software subscription will typically generate 80% of the company revenue. Secondary sources of revenue are services associated with the software implementation such as training and implementation services and expected to comprise 20% of the company's revenue. The company has created two product capabilities - a base module Clinical Trial Management System (CTMS) and an optional electronic trial master file (eTMF) module. The company determines the band of charge a customer will fall into based on its industry segment and number of active clinical trials that are run by the organisation